Hormones in Cancer Treatment

  • F. Cavalli


About one-quarter of all tumors are considered to be hormone-sensitive: different forms of hematologic malignancies belong to this group, since treatment with corticosteroids plays an important antitumor role in these diseases. Hormone responsiveness, which was strikingly demonstrated as early as 1898 by Beatson, who performed the first oophorectomy for breast cancer, represents an intringuing biologic phenomenon, since it opposes the often held dogma of a complete autonomy of the tumor growth. This may be more understandable today, now that our biologic comprehension of oncogenesis is rapidly evolving.


Breast Cancer Clin Oncol Endocrine Treatment Advanced Breast Cancer Endometrial Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alberto P, Mermillod B, Kaplan E et al (1985) A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone. Eur J Cancer Clin Oncol 21: 423–428PubMedCrossRefGoogle Scholar
  2. Allegra JC, Barlock A, Huff KK et al. (1980) Changes in multiple or sequential oestrogen receptor determinations in breast cancer. Cancer 45: 792–794PubMedCrossRefGoogle Scholar
  3. Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4: 186–193Google Scholar
  4. Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappelaere P (1985) Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mgandl g/day. Eur J Cancer Clin Oncol 21:1153–1158PubMedCrossRefGoogle Scholar
  5. Brunner KW, Sonntag RW, Alberto P, Senn HJ, Martz G, Obrecht P, Maurice P (1977) Combined chemo- and hormonal therapy in advanced breast cancer. Cancer 39: 2923–2933PubMedCrossRefGoogle Scholar
  6. Cavalli F, Beer M, Martz G et al. (1983 a) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer. Br Med J 1: 5–8CrossRefGoogle Scholar
  7. Cavalli F, Pedrazzini A, Martz G et al. (1983 b) A randomized trial of three different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Eur J Clin Oncol 19: 1615–1624CrossRefGoogle Scholar
  8. Cavalli F, Goldhirsch A, Jungi F et al. (1984) A randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2: 414–419PubMedGoogle Scholar
  9. Clark GM, Osborne CK, McGuire WL (1984) Correlations between oestrogen receptor, progesterone receptor and patients characteristics in human breast cancer. J Clin Oncol 2:1102–1109PubMedGoogle Scholar
  10. Cocconi G, De Lisi V, Boni C et al. (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. Cancer 51: 581–585PubMedCrossRefGoogle Scholar
  11. Dao TL (1972) Ablation therapy for hormone-dependent tumours. Annu Rev Med 23: 1–8PubMedCrossRefGoogle Scholar
  12. Ehrlich CE, Young PCM, Cleary RE (1981) Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 141: 539–546PubMedGoogle Scholar
  13. Fabian C, Sternson L, Barnett M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 64: 765–773PubMedGoogle Scholar
  14. Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Am J Clin Oncol 4: 237–248Google Scholar
  15. Fisher B, Redmond C, Brown A (1986) Adjuvant chemotherapy with and without tamoxifen in treatment of primary breast cancer: 5-year results from the NSABP trial. J Clin Oncol 4: 459–471PubMedGoogle Scholar
  16. Goldhirsch A, Gelber RD, Mouridsen H (1986) Endocrine aspects in adjuvant therapy for early breast cancer. In: Cavalli F, (ed) Endocrine therapy of breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 91–108 (ESO Monographs)CrossRefGoogle Scholar
  17. Henderson IC, Canellos GP (1980) Cancer of the breast. The past decade. N Engl J Med 302: 17–30, 78–90PubMedCrossRefGoogle Scholar
  18. Hull DF, Clark GM, Osborne CK et al. (1983) Multiple oestrogen receptor assays in human breast cancer. Cancer Res 43: 413–416PubMedGoogle Scholar
  19. Ingle JN, Krook JE, Gree SJ, Kubista TP, Evanson LL, Almann DL, Chang MN, Bisel HF, Windschitl HE, Twito SI, Pfeifle DM (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185PubMedGoogle Scholar
  20. Jordan VC (1986) Tamoxifen prophylaxis: prevention is better than cure - prevention is cure? In: Cavalli F, (ed) Endocrine therapy of breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 117–120 (ESO Monographs)CrossRefGoogle Scholar
  21. Kauppila A, Kujansun E, Vikko R (1982) Cytosal oestrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin. Cancer 50: 2157–2162PubMedCrossRefGoogle Scholar
  22. King RJB (1986) Experimental strategies for studying the development of breast cancer with special reference to hormones, growth factors and oncogenes. In: Cavalli F, (ed) Endocrine therapy of breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 5–26 (ESO Monographs)CrossRefGoogle Scholar
  23. King RJB, Stewart JF, Millis RR et al. (1982) Quantitative comparison of estradiol and progesterone receptor contents of primary and metastatic breast tumors in relation to response to endocrine treatment. Breast Cancer Res Treat 2: 339–346CrossRefGoogle Scholar
  24. Klein LA (1979) Prostatic carcinoma. N Engl J Med 300:824–833PubMedCrossRefGoogle Scholar
  25. Lippman ME, Chabner BA (1986) Editorial overview. NCI Monograph 1: 29–34Google Scholar
  26. Manni A, Pearson OH (1980) Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64: 779–785PubMedGoogle Scholar
  27. McClelland RA, Berger U, Miller LS et al. (1986) Immunocyto-chemical assay for oestrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res [Suppl] 46: 4241–4243Google Scholar
  28. McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428–433PubMedGoogle Scholar
  29. Meakin JW, Allt WEC, Beale FA et al. (1983) Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 3: 45–48CrossRefGoogle Scholar
  30. Mouridsen HT (1986) Endocrine treatment of advanced breast cancer. In: Cavalli F, (ed) Endocrine therapy of breast cancer. Springer, Berlin Heidelberg New York Tokyo, pp 79–90 (ESO Monographs)CrossRefGoogle Scholar
  31. Osborne CK (1985) Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 12: 317–326PubMedGoogle Scholar
  32. Pritchard KI, Thomson DB, Myers RE, Sutherland DJD, Mobbs BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796PubMedGoogle Scholar
  33. Robin PE, Dalton GA (1977) The role of major endocrine ablation. In: Stoll BA, (ed) Breast cancer management - early and late. Year Book, Chicago, pp 147–156Google Scholar
  34. Rose C, Mouridsen HT(1984) Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res 91: 230–242Google Scholar
  35. Ross MB, Buzdar AU, Blumenschein GR (1982) Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49: 413–417PubMedCrossRefGoogle Scholar
  36. Santen RJ, Wells SA (1980) The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 46: 1066–1074PubMedCrossRefGoogle Scholar
  37. Smith IE, Harris AL, Morgan M et al. (1981) Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised cross-over trial. Br Med J 283: 1432–1434CrossRefGoogle Scholar
  38. Taylor SG, Gelman RS, Falkson G et al. (1986) Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104: 455–461PubMedGoogle Scholar
  39. Thorpe SM, Koenders A (1986) Standardization of steroid receptor assays in human breast cancer. Eur J Cancer Clin Oncol 22: 939–945PubMedCrossRefGoogle Scholar
  40. Torti FM (1984) Hormonal therapy for prostate cancer. N Engl J Med 311: 1313–1314PubMedCrossRefGoogle Scholar
  41. Wada T, Koyama H, Teresawa T (1981) Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65: 728–729PubMedGoogle Scholar
  42. Zava DT, Goldhirsch A (1983) Oestrogen receptor in malignant melanoma: fact or artefact. Eur J Cancer Clin Oncol 19: 1151–1159PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • F. Cavalli

There are no affiliations available

Personalised recommendations